Moderna's zika vaccine shows promise in Mid-Stage trial

NCT ID NCT04917861

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested Moderna's experimental Zika vaccine, mRNA-1893, in 808 healthy adults aged 18 to 65. Participants received one of two doses or a placebo, and researchers monitored side effects and immune responses. The goal was to confirm the vaccine's safety and ability to produce antibodies against the Zika virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mRNA-1893 Zika vaccine
What this could lead to
If successful, this could lead to a safe and effective vaccine to prevent Zika virus infection, protecting people in affected regions.
What could go wrong
This is a Phase 2 trial focused on safety and immune response, not yet proving the vaccine prevents disease. Results may not guarantee effectiveness in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ZIKA VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Benchmark Research - Fort Worth

    Fort Worth, Texas, 76135, United States

  • Carribean Medical Research

    San Juan, PR, 00918, Puerto Rico

  • Clinical Research Puerto Rico, Inc.

    Guayama, PR, 00784, Puerto Rico

  • Clinical Research Puerto Rico, Inc.

    San Juan, PR, 00909, Puerto Rico

  • GCM Medical Group, PSC

    San Juan, PR, 00917, Puerto Rico

  • Johnson County Clin-Trials

    Lenexa, Kansas, 66219, United States

  • Latin Clinical Trial Center, Inc.

    San Juan, PR, 00909, Puerto Rico

  • Meridian Clinical Research (Sioux City, IA)

    Sioux City, Iowa, 51106, United States

  • Ponce Medical School Foundation, Inc.

    Ponce, PR, 00713, Puerto Rico

  • Ponce Medical School Foundation, Inc.

    Ponce, PR, 00716, Puerto Rico

  • University of Puerto Rico

    San Juan, PR, 00935, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.